Phase II and Pharmacologie Study of Docetaxel as Initial Chemotherapy for Metastatic Breast Cancer
Antineoplastic Agents, Phytogenic
Docetaxel is active for metastatic breast cancer. Neutropenia and fluid retention are dose-limiting. The AUC did not predict toxicity, but caution is warranted when treating patients with liver dysfunction. An understanding of the pathophysiology of the fluid retention may facilitate prevention. Frequent HSR may warrant prophylactic premedication.